| Literature DB >> 28787007 |
Edoardo Giacopuzzi1, Massimo Gennarelli1,2, Alessandra Minelli1, Rita Gardella1, Paolo Valsecchi3,4, Michele Traversa1, Cristian Bonvicini2, Antonio Vita3,4, Emilio Sacchetti3,4, Chiara Magri1.
Abstract
Inbreeding is a known risk factor for recessive Mendelian diseases and previous studies have suggested that it could also play a role in complex disorders, such as psychiatric diseases. Recent inbreeding results in the presence of long runs of homozygosity (ROHs) along the genome, which are also defined as autozygosity regions. Genetic variants in these regions have two alleles that are identical by descent, thus increasing the odds of bearing rare recessive deleterious mutations due to a homozygous state. A recent study showed a suggestive enrichment of long ROHs in schizophrenic patients, suggesting that recent inbreeding could play a role in the disease. To better understand the impact of autozygosity on schizophrenia risk, we selected, from a cohort of 180 Italian patients, seven subjects with extremely high numbers of large ROHs that were likely due to recent inbreeding and characterized the mutational landscape within their ROHs using Whole Exome Sequencing and, gene set enrichment analysis. We identified a significant overlap (17%; empirical p-value = 0.0171) between genes inside ROHs affected by low frequency functional homozygous variants (107 genes) and the group of most promising candidate genes mutated in schizophrenia. Moreover, in four patients, we identified novel and extremely rare damaging mutations in the genes involved in neurodevelopment (MEGF8) and in GABA/glutamatergic synaptic transmission (GAD1, FMN1, ANO2). These results provide insights into the contribution of rare recessive mutations and inbreeding as risk factors for schizophrenia. ROHs that are likely due to recent inbreeding harbor a combination of predisposing low-frequency variants and extremely rare variants that have a high impact on pivotal biological pathways implicated in the disease. In addition, this study confirms that focusing on patients with high levels of homozygosity could be a useful prioritization strategy for discovering new high-impact mutations in genetically complex disorders.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28787007 PMCID: PMC5546675 DOI: 10.1371/journal.pone.0182778
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Pipeline for filtration of low frequency functional variants.
ROH regions in ROH-individuals.
| Patient | Number of ROHs >1Mb | Median dimension (bp) | Max dimension (bp) | Amount of the genome | Number of genes within ROHs |
|---|---|---|---|---|---|
| N° 1 | 26 | 2,468,705 | 13,889,443 | 82,551,340 | 764 |
| N° 2 | 76 | 1,602,416 | 5,538,899 | 151,738,690 | 1,430 |
| N° 3 | 28 | 2,610,206 | 12,005,057 | 108,730,336 | 861 |
| N° 4 | 25 | 1,602,559 | 20,857,920 | 87,043,015 | 677 |
| N° 5 | 51 | 2,890,666 | 12,377,762 | 219,863,310 | 1,538 |
| N° 6 | 48 | 2,560,178 | 10,334,938 | 147,737,251 | 1,214 |
| N° 7 | 42 | 3,268,145 | 9,268,459 | 144,180,390 | 1,216 |
Number of variants in ROH regions.
| Patient | Variants | LFF variants | LFF variants in genes expressed in brain | LFF-D variants | “Best candidate” variants |
|---|---|---|---|---|---|
| N°1 | 1,064 | 15 (15) | 6 (6) | 7 (7) | |
| N°2 | 1,561 | 27 (25) | 14 (14) | 14 (14) | 1 |
| N°3 | 1,217 | 24 (16) | 7 (7) | 4 (4) | 1 |
| N°4 | 991 | 7 (7) | 3 (3) | 3 (3) | |
| N°5 | 1,988 | 24 (21) | 13 (11) | 9 (9) | |
| N°6 | 1,711 | 9 (9) | 5 (5) | 2 (2) | 1 |
| N°7 | 1,579 | 14 (14) | 8 (8) | 6 (6) | 1 |
LFF = low frequency functional variants; LFF-D = low frequency damaging variants
a in parenthesis the number of genes affected by the variants.
b Total number of different variants
List of “best candidate” variants.
| Patient | Variants | Gene | Gene ID | cDNA nucleotide | AA | SIFT | PP2_HDIV | MT | PP | Frequency | ROH size |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N°2 | chr19:42840266G>A | NM_001271938 | c.1012G>A | p.Ala338Thr | 0.90 (T) | 0.999 (D) | 1 (D) | 5.141 | Novel | 3.3 Mb | |
| N°3 | chr12:5963280G>A | NM_001278596 | c.562C>T | p.Arg188Trp | 0.00 (D) | 1.000 (D) | 1 (D) | 4.955 | 0.0000664 | 6.9 Mb | |
| N°6 | chr2:171687546A>G | NM_000817 | c.391A>G | p.Thr131Ala | 0.02 (D) | 0.986 (D) | 1 (D) | 8.962 | Novel | 5.8 Mb | |
| N°7 | chr15:33256378G>C | NM_001103184 | c.2399C>G | p.Ser800Cys | 0.06 (T) | 1.00 (D) | 0.99 (D) | 9.435 | 0.00000828 | 4.0 Mb |
SIFT: Sorting Intolerant from Tolerant algorithm; PP2_HDIV: Polyphen2_HDIV; MT: Mutation Taster; D = predicted as probably damaging, deleterious or disease causing; T = tolerated.
a positions are referred to the Hg19 assembly.
b Frequency refers to allele frequency reported in the ExAC0.2 database; none of the variants have been reported in homozygous state.
c Size of ROHs where the “best candidate” mutations were identified.
Fig 2Localization at the synaptic level of the FMN1, ANO2 and GAD1 gene products on a hippocampal neuronal circuit.
FMN1 protein and calcium-activated ANO2 chloride channels are expressed in the dendritic spines of excitatory synapses [22, 23], whereas GAD67 (the enzyme produced by the GAD1 gene) is expressed in the axonal termini of inhibitory GABAergic interneurons. It has been shown that impairment of these genes induces: dendritic arborization abnormalities (FMN1) [23], alterations in action potential duration and in the threshold for action potential generation (ANO2) [22], and the dysfunctional synthesis of the GABA neurotransmitter (GAD1) [24]. At different levels, the impairment of these genes might affect the complex excitatory/inhibitory balance across cortical circuits that is believed to be altered in schizophrenic patients [25].